Connect with us

Science

Best Stocks To Invest In Right Now? 3 Biotech Stocks To Know

Check out these biotech players under the microscope now.
The post Best Stocks To Invest In Right Now? 3 Biotech Stocks To Know appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Published

on

3 Biotech Stocks For Your June Watchlist

When looking for the most active stocks today, investors would likely think of meme stocks. However, biotech stocks may also come to mind as well in the stock market today. As most seasoned investors would know, the biotech industry is jam-packed with exciting news for traders to digest. Namely, the biotech industry is filled with companies that conduct research on life-improving treatments. Given the vast array of illnesses to be cured today, investors would have plenty of companies to choose from now.

For instance, a very prominent example would be COVID-19. Following the outbreak of the pandemic, countless biotech companies sprang into action to develop a vaccine. Now, companies such as Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) are in the spotlight thanks to their vaccines. In the case of Moderna, the company’s vaccine continues to make its way across the globe now. Just yesterday, news broke of the U.S. government reportedly being in negotiations with Moderna to secure additional vaccine doses for other countries. Elsewhere, investors appear keen on Novavax’s upcoming vaccine candidate as well. Analysts from both B. Riley Securities and Jefferies hit the company’s shares with a Buy rating, citing that the company is nearing regulatory approval. As it stands, both MRNA stock and NVAX stock have more than tripled in value over the past year.

At the same time, even the bigger names in the biotech field are not sitting idly by. Take Biogen (NASDAQ: BIIB) for example who just received FDA approval for its Alzheimer’s treatment this week, an industry first. As a result, BIIB stock is currently looking at gains of over 40% this week. With all that in mind, here are three trending biotech stocks in the stock market now.

Best Biotech Stocks To Buy [Or Sell] Now

BioNTech

Starting us off today is BioNTech, the other half to the pioneering Pfizer (NYSE: PFE) vaccine. For the uninitiated, BioNTech is a German biotech company that develops and manufactures active immunotherapies. Aside from the coronavirus vaccine, the company’s developmental pipeline also focuses heavily on a wide array of cancers. Through this comprehensive oncology pipeline, BioNTech is currently working with healthcare players such as Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY). Now, BNTX stock is currently looking at gains of over 400% in the past year. Could it still have room to run this year?

Well, for one thing, the company’s work in the coronavirus vaccine field is far from over. Late last month, BioNTech’s vaccine candidate received its first authorization in the European Union for use in adolescents. Given the age group’s arguably underdeveloped immune systems, this is a remarkable development for BioNTech. According to the company, the vaccine can now be applied to individuals between the ages of 12 to 15 years old. Not only would this serve to accelerate vaccination efforts globally, but it would also provide BioNTech with additional market reach.

If that wasn’t enough, the company could also be getting additional orders from the U.S. According to the Washington Post, the Biden administration is looking to buy 500 million doses of BioNTech’s vaccine to redistribute to other countries. For now, it is estimated that all doses will likely be distributed by the first half of 2022. Covax, the World Health Organization (WHO)-backed initiative, will be in charge of the global distribution. By and large, this marks a win-win situation as BioNTech can market more vaccines while countries in need receive critical aid. Does this make BNTX stock a top buy for you now?

Source: TD Ameritrade TOS


Read More

Inovio Pharmaceuticals Inc.

Another biotech company to know now would be Inovio Pharmaceuticals Inc. In brief, the company primarily focuses on the discovery, development, and commercialization of synthetic DNA products. Said products serve to treat infectious diseases, cancer, and sexually transmitted diseases. Moreover, Inovio also boasts a massive list of notable partners and collaborators from both governments and private organizations. These include but are not limited to AstraZeneca (NASDAQ: AZN), the Bill & Melinda Gates Foundation, the U.S. Department of Defense, and the National Institutes of Health.

Impressive operations aside, INO stock appears to be catching investors’ attention now. This appears to be the case as the company’s shares are up by over 45% in the past month. For the most part, this would be thanks to the company’s work on its supposed DNA vaccine, INO-4802. As of last month, Inovio’s vaccine candidate produced strong signs of efficacy across multiple strains of the virus in preclinical studies. Notably, this could potentially make it a “next-generation Pan-COVID-19 vaccine candidate”, according to Inovio.

Aside from that, the company is also hard at work on its earlier COVID-19 vaccine candidate INO-4800 as well. Earlier today, Inovio announced that it would be expanding its current partnership with Chinese biotech company, Advaccine. The duo will now be conducting global Phase 3 trials for INO-4800 in a two-dose regimen. In terms of subjects, individuals 18 years and older across the Latin America and Asia regions will be involved. CEO Dr. Joseph Kim cites global vaccination rates being below 10% as a key driver to accelerate these tests. Could INO stock be worth adding to your portfolio because of all this?

best biotech stocks to buy (INO stock)
Source: TD Ameritrade TOS

[Read More] 4 Artificial Intelligence Stocks To Watch Right Now

Connect Biopharma Holdings Ltd

Following that, we have Connect Biopharma. For some context, it is a global clinical-stage biopharmaceutical company looking to treat patients with chronic inflammatory diseases. It does so via the development of therapies derived from T cell-based research. For a sense of scale, the company has operations in China, the U.S., and Australia. On top of that, Connect Biopharma also runs additional clinical development activities in Europe. In a nutshell, the company uses small molecules and antibodies to target T cells, which in turn serve to screen and discover potent drug candidates.

If anything, Connect Biopharma’s portfolio continues to expand significantly and investors seem to be reacting accordingly. Diving right into it, the company announced the commencement of a Phase 2 trial for its Asthma treatment, CBP-201. Since the announcement early on May 12, CNTB stock has surged by over 20%. Specifically, the treatment is being evaluated for use in adults with moderate-to-severe persistent asthma. Approximately 300 patients across 80 clinical sites in the U.S., China, the European Union, the U.K., Ukraine, and South Korea.

According to Dr. Edward Kerwin, founder of the Clinical Research Institute, Allergy and Asthma Center, this is a significant development. He said, “Beginning enrollment on the CBP-201 clinical trial offers hope in the pursuit of new, effective treatments for severe asthma.” Given the scale and importance of Connect Biopharma’s latest project, we could be looking at exciting times ahead for CNTB stock. Would you agree?

best biotech stocks to buy right now (CNTB stock)
Source: TD Ameritrade TOS

The post Best Stocks To Invest In Right Now? 3 Biotech Stocks To Know appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Spread & Containment

AstraZeneca antibody cocktail fails to prevent Covid-19 symptoms in large trial

AstraZeneca said a late-stage trial failed to provide evidence that the company’s Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

Published

on

Astra antibody cocktail fails to prevent COVID-19 symptoms in large trial

(Reuters; )

June 15 (Reuters) – AstraZeneca (AZN.L) said on Tuesday a late-stage trial failed to provide evidence that its COVID-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms.

The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.

The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.

Results for a subset of participants who were not infected to begin with was more encouraging but the primary analysis rested on results from all participants.

FILE PHOTO: A computer image created by Nexu Science Communication together with Trinity College in Dublin, shows a model structurally representative of a betacoronavirus which is the type of virus linked to COVID-19, better known as the coronavirus linked to the Wuhan outbreak, shared with Reuters on February 18, 2020. NEXU Science Communication/via REUTERS

“While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” AstraZeneca Executive Vice President Mene Pangalos said in a statement.

The company is banking on further studies to revive the product’s fortunes. Five more trials are ongoing, testing the antibody cocktail as treatment or in prevention.

The next one will likely be from a larger trial testing the product in people with a weakened immune system due to cancer or an organ transplant, who may not benefit from a vaccine.

TARGETED ALTERNATIVES

AZD7442 belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections.

Similar therapies developed by rivals Regeneron (REGN.O) and Eli Lilly (LLY.N) have been approved by U.S. regulators for treating unhospitalised COVID patients.

European regulators have also authorised Regeneron’s therapy and are reviewing those developed by partners GlaxoSmithKline (GSK.L) and Vir Biotechnology (VIR.O) as well as by Lilly and Celltrion (068270.KS).

Regeneron is also seeking U.S. authorisation for its therapy as a preventative treatment.

But the AstraZeneca results are a small blow for the drug industry as it tries to find more targeted alternatives to COVID-19 inoculations, particularly for people who may not be able to get vaccinated or those who may have an inadequate response to inoculations.

The Anglo-Swedish drugmaker, which has faced a rollercoaster of challenges with the rollout of its COVID-19 vaccine, is also developing new treatments and repurposing existing drugs to fight the virus.

AstraZeneca also said on Tuesday it was in talks with the U.S. government on “next steps” regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza (LONN.S) was contracted to produce AZD7442.

Shares in the company were largely unchanged on the London Stock Exchange.

The full results will be submitted for publication in a peer-reviewed medical journal, the company said.

Reporting by Vishwadha Chander in Bengaluru; Editing by Shounak Dasgupta

Our Standards: The Thomson Reuters Trust Principles.

 

Reuters source:

https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-says-its-antibody-treatment-failed-in-preventing-covid-19-exposed-2021-06-15

 

Read More

Continue Reading

Government

Former FDA Head Takes on Exec Role at Flagship’s Preemptive Health Initiative

Stephen Hahn, the Commissioner of the U.S. Food and Drug Administration under former President Donald Trump, took on a new role as chief medical officer of a new health security initiative launched by Flagship Pioneering, a life sciences venture firm…

Published

on

Former FDA Head Takes on Exec Role at Flagship’s Preemptive Health Initiative

 

Stephen Hahn, the Commissioner of the U.S. Food and Drug Administration (FDA) under former President Donald Trump, has taken on a new role as chief medical officer of a new health security initiative launched by Flagship Pioneering, a life sciences venture firm that incubates and curates biopharma companies.

First announced Monday, Flagship’s Preemptive Medicine and Health Security initiative aimed at developing products that can help people before they get sick. This division will focus on infectious disease threats and pursue bold treatments for existing diseases, including cancer, obesity, and neurodegeneration. 

In a brief statement, Hahn, who served as commissioner from December 2019 until January 2021, said the importance of investing in innovation and preemptive medications has never been more apparent. 

“In my career I have been a doctor and a researcher foremost and it is an honor to join Flagship Pioneering in its efforts to prioritize innovation, particularly in its Preemptive Medicine and Health Security Initiative. The more we can embrace a “what if …” approach the better we can support and protect the health and well-being of people here in the U.S. and around the world,” Hahn said in a statement. 

During his time at the FDA, Hahn was at the forefront of the government’s effort to battle the COVID-19 pandemic. His office oversaw the regulatory authorization of antivirals, antibody therapeutics and vaccines, as well as diagnostics and other tools to battle the novel coronavirus. 

Kevin Dietsch-Pool/Getty Images

Hahn bore the brunt of verbal barbs aimed at the FDA by the former president for not rushing to authorize a vaccine for COVID-19 ahead of the November 2020 election. The second vaccine authorized by the FDA for COVID-19 was developed by Moderna, a Flagship company. 

Prior to his confirmation as FDA Commissioner, Hahn, a well-respected oncologist, served as chief medical executive of the vaunted The University of Texas MD Anderson Cancer Center. Hahn was named deputy president and chief operating officer in 2017. In that role, he was responsible for the day-to-day operations of the cancer center, which includes managing more than 21,000 employees and a $5.2 billion operating budget. He was promoted to that position two years after joining MD Anderson as division head, department chair and professor of Radiation Oncology. Prior to MD Anderson, Hahn served as head of the radiation oncology department at the University of Pennsylvania’s Perelman School of Medicine.

Flagship Founder and Chief Executive Officer Noubar Afeyan said the COVID-19 pandemic that shut down economies and caused the deaths of more than 3.8 million people across the world was an important reminder that health security is a top global priority. In addition, the ongoing pandemic brings into “stark focus” the importance of preemptive medications. 

Hahn, who helmed the FDA for three years and before that served as chief medical executive at The University of Texas MD Anderson Cancer Center, has extensive experience overseeing clinical and administrative programs. Afeyan said the new division would benefit from Hahn’s experience as FDA Commissioner and help steer the Preemptive Medicine and Health Security initiative as it explores Flagship’s “growing number of explorations and companies in this emerging field.”

It is not unusual for former FDA heads to take prominent roles with companies. For example, former FDA Commissioner Scott Gottlieb, Trump’s first FDA Commissioner, took a position on the Pfizer Board of Directors weeks after departing his government role. He has also taken positions on other boards since then, including Aetion, FasterCures and Illumina.

 

BioSpace source:

https://www.biospace.com/article/former-fda-head-stephen-hahn-takes-cmo-role-at-flagship-pioneering-preemptive-health-initiative-

 

Read More

Continue Reading

Government

Five U.S. states had coronavirus infections even before first reported cases – study

At least seven people in five U.S. states were infected with the novel coronavirus weeks before those states reported their first cases, a new government study showed.

Published

on

Five U.S. states had coronavirus infections even before first reported cases – study

(Reuters) – At least seven people in five U.S. states were infected with the novel coronavirus weeks before those states reported their first cases, a new government study showed.

Participants who reported antibodies against SARS-CoV-2 were likely exposed to the virus at least several weeks before their sample was taken, as the antibodies do not appear until about two weeks after a person has been infected, the researchers said.

The latest results build on findings from a Centers for Disease Control and Prevention study that suggested the novel coronavirus may have been circulating in the United States last December, well before the first COVID-19 case was diagnosed on Jan. 19, 2020.

A protective face mask lays, as the global outbreak of the coronavirus disease (COVID-19) continues, beside leaves at the lakefront in Chicago, Illinois, U.S., December 6, 2020. REUTERS/Shannon/File Photo

The positive samples came from Illinois, Massachusetts, Mississippi, Pennsylvania and Wisconsin, and were part of a study of more than 24,000 blood samples taken for a National Institutes of Health research program between Jan. 2 and March 18, 2020.

Samples from participants in Illinois were collected on Jan. 7 and Massachusetts on Jan. 8, suggesting that the virus was present in those states as early as late December.

“This study allows us to uncover more information about the beginning of the U.S. epidemic,” said Josh Denny, one of the study authors.

The findings were published in the journal Clinical Infectious Diseases.

Reporting by Mrinalika Roy in Bengaluru; Editing by Anil D’Silva

Our Standards: The Thomson Reuters Trust Principles.

 

Reuters source:

https://www.reuters.com/business/healthcare-pharmaceuticals/five-us-states-had-coronavirus-infections-even-before-first-reported-cases-study-2021-06-15

 

Read More

Continue Reading

Trending